Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Glaucoma Market?

There has been a substantial growth in the glaucoma market size in the past few years. The market value that stands at $7.76 billion in 2024 is predicted to rise to $8.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%. The significant growth during the historic period is a result of heightened awareness about eye health, increased healthcare expenditure, widespread adoption of telemedicine for eye management, enhanced healthcare infrastructure, and a rise in government initiatives towards healthcare.

What Growth Rate Is Forecasted for the Glaucoma Market by 2029?

The market size for glaucoma is set to undergo significant expansion in the coming years. The predicted growth is to reach $10.20 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%. This growth during the forecast period can be related to factors such as an increasing elderly population, a surge in glaucoma prevalence, an escalating demand for minimally invasive surgical procedures, and a rise in diabetes and hypertension cases. Further, the forecast period is likely to witness trends like improvements in diagnostic technology, introduction of new medicinal treatments, technological breakthroughs in surgical equipment, combined therapy options, and the implementation of robotic surgeries.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

Which Key Companies Are Shaping the Future of the Glaucoma Market?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Which Factors Are Driving Demand in the Glaucoma Industry?

The increasing occurrence of chronic eye diseases is predicted to spur the expansion of the glaucoma market in the future. Chronic eye diseases, which often lead to lasting visual impairment or discomfort demanding continuous care or therapy, are long-standing issues of the eyes. Due to factors such as an aging population, increased exposure to screens, lifestyle practices, and a higher presence of diseases like diabetes and hypertension, there is a surge in these chronic eye diseases. Glaucoma treatment is crucial for handling chronic eye diseases, as it helps to decrease intraocular pressure, hinder additional optic nerve disintegration, and protect vision. If glaucoma is left untreated, it can culminate in uncorrectable blindness. For instance, the National Health Service (NHS), a publicly funded healthcare institution in the UK, reported in December 2024 that over 2 million UK individuals were grappling with sight loss that year. In addition, the projections suggest a 27% rise in the number of individuals suffering from sight loss by 2035, reaching an estimated 2.8 million. Consequently, the escalating incidence of chronic eye diseases is fueling the surge of the glaucoma market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

How Is the Glaucoma Market Segmented by Several Divisions?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

What are the Emerging Market Trends Driving the Growth of the Glaucoma Industry?

Key players in the glaucoma market are focusing their efforts on the development of innovative treatments, such as Rho-kinase (ROCK) inhibitors. These advancements offer a dual-pronged strategy for reducing intraocular pressure, working both to improve the outflow of aqueous humor and to loosen trabecular meshwork cells. This dual-action mechanism makes them highly effective in glaucoma treatment. Rho-kinase inhibitors are a type of drug that specifically targets the inhibitory action of Rho-kinase enzymes, which control cell contraction and thus alleviate glaucoma by decreasing intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., a Japanese firm specialising in eye care, introduced Roclanda to the UK market. Roclanda, a fixed-dose combination (FDC) of latanoprost and netarsudil (a new type of Rho-kinase inhibitor), effectively lowers intraocular pressure by targeting malfunctioning trabecular meshwork. It’s prescribed for adults with primary open-angle glaucoma or ocular hypertension who haven’t responded effectively to monotherapy using a prostaglandin or netarsudil. The arrival of Roclanda in Europe signifies the debut of a new category of glaucoma medication in a quarter of a century, indicating a significant leap in treatment solutions. Through the synergy of netarsudil and latanoprost, Roclanda enhances outflow via both the traditional (trabecular) and the unconventional (uveoscleral) pathways, offering a holistic strategy for managing increased intraocular pressure.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Which Regions Are Driving Growth in the Glaucoma Market?

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

This Report Delivers Insight On:

1. How big is the glaucoma market, and how is it changing globally?

2. Who are the major companies in the glaucoma market, and how are they performing?

3. What are the key opportunities and risks in the glaucoma market right now?

4. Which products or customer segments are growing the most in the glaucoma market?

5. What factors are helping or slowing down the growth of the glaucoma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model